171 related articles for article (PubMed ID: 9989621)
1. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates.
Plomp JJ; Molenaar PC; O'Hanlon GM; Jacobs BC; Veitch J; Daha MR; van Doorn PA; van der Meché FG; Vincent A; Morgan BP; Willison HJ
Ann Neurol; 1999 Feb; 45(2):189-99. PubMed ID: 9989621
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding.
Jacobs BC; O'Hanlon GM; Bullens RW; Veitch J; Plomp JJ; Willison HJ
Brain; 2003 Oct; 126(Pt 10):2220-34. PubMed ID: 12876146
[TBL] [Abstract][Full Text] [Related]
3. Concanavalin A inhibits pathophysiological effects of anti-ganglioside GQ1b antibodies at the mouse neuromuscular synapse.
Bullens RW; Halstead SK; O'Hanlon GM; Veitch J; Molenaar PC; Willison HJ; Plomp JJ
Muscle Nerve; 2005 Jun; 31(6):751-60. PubMed ID: 15793847
[TBL] [Abstract][Full Text] [Related]
4. Detection and prevalence of alpha-latrotoxin-like effects of serum from patients with Guillain-Barré syndrome.
Jacobs BC; Bullens RW; O'Hanlon GM; Ang CW; Willison HJ; Plomp JJ
Muscle Nerve; 2002 Apr; 25(4):549-58. PubMed ID: 11932973
[TBL] [Abstract][Full Text] [Related]
5. Anti-GQ1b antibodies and evoked acetylcholine release at mouse motor endplates.
Bullens RW; O'Hanlon GM; Goodyear CS; Molenaar PC; Conner J; Willison HJ; Plomp JJ
Muscle Nerve; 2000 Jul; 23(7):1035-43. PubMed ID: 10882997
[TBL] [Abstract][Full Text] [Related]
6. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.
Halstead SK; Zitman FM; Humphreys PD; Greenshields K; Verschuuren JJ; Jacobs BC; Rother RP; Plomp JJ; Willison HJ
Brain; 2008 May; 131(Pt 5):1197-208. PubMed ID: 18184663
[TBL] [Abstract][Full Text] [Related]
7. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome.
Buchwald B; Bufler J; Carpo M; Heidenreich F; Pitz R; Dudel J; Nobile-Orazio E; Toyka KV
Neurology; 2001 Jan; 56(1):67-74. PubMed ID: 11148238
[TBL] [Abstract][Full Text] [Related]
8. Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain-Barre syndromes.
Kanzaki M; Kaida K; Ueda M; Morita D; Hirakawa M; Motoyoshi K; Kamakura K; Kusunoki S
J Neurol Neurosurg Psychiatry; 2008 Oct; 79(10):1148-52. PubMed ID: 18339728
[TBL] [Abstract][Full Text] [Related]
9. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal.
O'Hanlon GM; Plomp JJ; Chakrabarti M; Morrison I; Wagner ER; Goodyear CS; Yin X; Trapp BD; Conner J; Molenaar PC; Stewart S; Rowan EG; Willison HJ
Brain; 2001 May; 124(Pt 5):893-906. PubMed ID: 11335692
[TBL] [Abstract][Full Text] [Related]
10. The relation of clinical symptoms and anti-ganglioside antibodies to MEPPs frequency increase in 8 cases of variant type Guillain-Barré syndrome.
Kishi M; Fujioka T; Miura H; Sekine A; Iguchi H; Nakazora H; Kiyozuka T; Igarashi O; Ichikawa Y; Sugimoto H; Kurihara T; Irie S; Saito T
J Peripher Nerv Syst; 2003 Jun; 8(2):82-90. PubMed ID: 12795712
[TBL] [Abstract][Full Text] [Related]
11. Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection.
Schwerer B; Neisser A; Bernheimer H
Infect Immun; 1999 May; 67(5):2414-20. PubMed ID: 10225903
[TBL] [Abstract][Full Text] [Related]
12. Anti-ganglioside complex antibodies in Miller Fisher syndrome.
Kaida K; Kanzaki M; Morita D; Kamakura K; Motoyoshi K; Hirakawa M; Kusunoki S
J Neurol Neurosurg Psychiatry; 2006 Sep; 77(9):1043-6. PubMed ID: 16614007
[TBL] [Abstract][Full Text] [Related]
13. Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury.
O'Hanlon GM; Humphreys PD; Goldman RS; Halstead SK; Bullens RW; Plomp JJ; Ushkaryov Y; Willison HJ
Brain; 2003 Nov; 126(Pt 11):2497-509. PubMed ID: 12937083
[TBL] [Abstract][Full Text] [Related]
14. Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release.
Roberts M; Willison H; Vincent A; Newsom-Davis J
Lancet; 1994 Feb; 343(8895):454-5. PubMed ID: 7905957
[TBL] [Abstract][Full Text] [Related]
15. [Guillain-Barré and Fisher syndromes: update on the pathophysiological role of antiganglioside antibodies].
Kaida K
Rinsho Shinkeigaku; 2012; 52(11):914-6. PubMed ID: 23196466
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunological spectrum of the Miller Fisher syndrome.
Lo YL
Muscle Nerve; 2007 Nov; 36(5):615-27. PubMed ID: 17657801
[TBL] [Abstract][Full Text] [Related]
17. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles.
Liu JX; Willison HJ; Pedrosa-Domellöf F
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3226-32. PubMed ID: 19255160
[TBL] [Abstract][Full Text] [Related]
18. Anti-GQ1b antibody does not affect neuromuscular transmission in human limb muscle.
Kuwabara S; Misawa S; Takahashi H; Sawai S; Kanai K; Nakata M; Mori M; Hattori T; Yuki N
J Neuroimmunol; 2007 Sep; 189(1-2):158-62. PubMed ID: 17673301
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in Miller Fisher syndrome and related disorders.
Overell JR; Willison HJ
Curr Opin Neurol; 2005 Oct; 18(5):562-6. PubMed ID: 16155441
[TBL] [Abstract][Full Text] [Related]
20. Differential blocking effects of the monoclonal anti-GQ1b IgM antibody and alpha-latrotoxin in the absence of complement at the mouse neuromuscular junction.
Buchwald B; Ahangari R; Toyka KV
Neurosci Lett; 2002 Dec; 334(1):25-8. PubMed ID: 12431767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
